– UK, London – AstraZeneca PLC (LON: AZN / STO: AZN / Nasdaq: AZN) announced the nomination of Dr. Karen Knudsen (Ph.D.) for her election to its Board as a Non-Executive Director at the AGM on 11 April 2025.
“I am very pleased Karen has accepted our invitation to join the Board. Subject to her election by shareholders at the AGM, as a globally-recognised cancer scientist with broad executive experience in oncology, she will be well-positioned in respect of the Board’s work. Karen’s deep knowledge of the US healthcare industry and medical academic environment also makes her a great fit for AstraZeneca. Her proposed appointment to the Board’s Science Committee and Sustainability Committee reflects the broad contribution I believe she will make to AstraZeneca’s success,” said Board Chair, Michel Demaré.
Karen Knudsen would also join the Science and Sustainability Committees if elected.
Deborah DiSanzo and Andreas Rummelt will not stand for re-election and will retire from the Board at the end of the AGM on 11 April 2025.
About Karen Knudsen
Karen Knudsen is a globally recognized cancer scientist and executive leader. She has a track record of translational discoveries in advanced prostate cancer that shaped understanding and treatment approaches and expertise in healthcare innovation, strategic partnerships, and organizational growth. Most recently, she served as CEO of the American Cancer Society and its advocacy affiliate, ACS Cancer Action Network, where she led the organization through a period of transformative growth, increasing revenue and expanding research, advocacy, and patient support.
Karen Knudsen served as Hilary Koprowski Endowed Professor and Chair of Cancer Biology at Thomas Jefferson University and Enterprise Director of the Sidney Kimmel Comprehensive Cancer Center, a National Cancer Institute-designated center of excellence. Karen has held various leadership roles in oncology, including EVP of Oncology Services at Jefferson Health and serving on the NCI Board of Scientific Advisors, as President of the Association of American Cancer Institutes, and on the Board of Directors of the American Association for Cancer Research. Her contributions to oncology and healthcare leadership have been recognized with numerous awards, including honors from the Endocrine Society, the Prostate Cancer Foundation, and the American Society for Clinical Oncology.
Karen Knudsen is Professor Emerita of Thomas Jefferson University and the Sidney Kimmel Comprehensive Cancer Center. She is an Independent Director of Exai Bio, and serves on the board of Research!America, and as a board adviser for ArteraAI.
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.
For more: https://www.astrazeneca.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.